Ipratropium bromide in the treatment of the 'rhinorrhoea syndrome'.
Conventional treatments for non-allergic perennial rhinitis have proven somewhat unsuccessful in the control of rhinorrhoea when it is the predominant symptom. Hence, a double-blind cross-over trial of Ipratropium, a parasympatholytic, and placebo were carried out over a 12-week period. There was a significant reduction in rhinorrhoea during active treatment, with the most noticeable effect being in the moderate-to-severe rhinorrhoea group. No significant effect was noted on nasal obstruction or sneezing and no serious side-effects were seen. A carry-on effect was noted when active treatment was used initially. However, the group given active treatment following placebo had a better result overall. A strong placebo effect was also noted in both groups, in keeping with a trial of this order.
O'Dwyer
T P
TP
Department of Otolaryngology, Eye & Ear Hospital, Dublin.
Lee
R J
RJ
Kaye
J
J
Fennell
G
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D001286:Atropine Derivatives / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012220:Rhinitis / Q000188:drug therapy*
D001286:Atropine Derivatives; D009241:Ipratropium